Monday, May 7, 2018
A pathobiology window in the “T-cell world”
Chairmen: E.S. Jaffe, S.A. Pileri
News from WHO
E.S. Jaffe
Defining vulnerabilities of PTCL
D.M. Weinstock
Standard treatment in front-line and prognostic index
Chairmen: F. Foss, S.M. Horwitz
How I treat:
PTCL
F.A. D'Amore
CTCL
Y.H. Kim
ATLL
K. Tsukasaki
NK/T-cell lymphoma
W.S. Kim
PET: to be or not to be?
B.D. Cheson
Prognostic models in PTCL
F. Foss
Tuesday, May 8, 2018
PTCL: morphology and pathobiology
Chairmen: B. Falini, M. Paulli
Molecular genotyping
T. Palomero
Gene expression profiling
J. Iqbal
ALCL
S.A. Pileri
The “CD30+ world”
Chairman: P.L. Zinzani
CD30 expression: is it a Rubik’s cube?
S.A. Pileri
Brentuximab vedotin in:
ALCL
B. Pro
PTCL-nos/AILT
S.M. Horwitz
CTCL
H.M. Prince
NK/T-cell lymphoma: SMILE and other “asparaginase” containing regimens
Chairmen: R. Advani, W.S. Kim
Experience in:
Japan
M. Yamaguchi
France
A. Jaccard
China
H. Huang
Korea
W.S. Kim
PTCL: update on...
Chairman: B.D. Cheson
Romidepsin
A.R. Shustov
Belinostat
F. Foss
Lenalidomide
S.M. Horwitz
Lectures
Chairman: A. Pinto
News on breast implant ALCL
H.M. Prince
PTCL: the new single agents
Chairmen: M. Ogura, E. Zucca
Aplidin
B. Pro
Duvelisib
S.M. Horwitz
PTCL
K. Tsukasaki
Wednesday, May 9, 2018
CTCL: morphology, pathobiology and prognostic models
Chairmen: E. Berti, S.A. Pileri
Histology
M. Santucci
Prognostic models
J. Scarisbrick
CTCL: conventional and emerging drugs
Chairmen: N. Pimpinelli, P. Quaglino
Histone deacetylase inhibitors
J. Scarisbrick
IPH4102 anti-KIR3DL2 mAb
M. Bagot
Duvelisib
S.M. Horwitz
Pembrolizumab
Y.H. Kim
Mogamulizumab: a pan-T cell lymphoma drug
Chairman: S.M. Horwitz
ATLL
K. Tsukasaki
PTCL
M. Ogura
Allotransplant setting
Chairman: F. Onida
North America
A.R. Shustov
Europe
P. Corradini
Europe
M. Bagot
